This is not the most recent version of the article. View current version (26 NOV 2014)

Intervention Protocol

You have free access to this content

Exercise for cancer cachexia in adults

  1. Antonio Jose Grande1,*,
  2. Valter Silva1,
  3. Matthew Maddocks2,
  4. Rachel Riera1,
  5. Alessandra Medeiros3,
  6. Simone G P Vitoriano4,
  7. Maria S Peccin5

Editorial Group: Cochrane Pain, Palliative and Supportive Care Group

Published Online: 27 OCT 2013

DOI: 10.1002/14651858.CD010804

How to Cite

Grande AJ, Silva V, Maddocks M, Riera R, Medeiros A, Vitoriano SGP, Peccin MS. Exercise for cancer cachexia in adults (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD010804. DOI: 10.1002/14651858.CD010804.

Author Information

  1. 1

    Centro de Estudos de Medicina Baseada em Evidências e Avaliação Tecnológica em Saúde, Brazilian Cochrane Centre, São Paulo, São Paulo, Brazil

  2. 2

    Cicely Saunders Institute, King's College London, Department of Palliative Care, Policy and Rehabilitation, London, UK

  3. 3

    Universidade Federal de São Paulo, Brazilian Cochrane Centre, Santos, São Paulo, Brazil

  4. 4

    APS Santa Marcelina, São Paulo, São Paulo, Brazil

  5. 5

    Universidade Federal de São Paulo, Department of Human Movement Sciences, Santos, São Paulo, Brazil

*Antonio Jose Grande, Brazilian Cochrane Centre, Centro de Estudos de Medicina Baseada em Evidências e Avaliação Tecnológica em Saúde, R. Borges Lagoa, 564 cj 63, São Paulo, São Paulo, 04038000, Brazil.

Publication History

  1. Publication Status: New
  2. Published Online: 27 OCT 2013


This is not the most recent version of the article. View current version (26 NOV 2014)



  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Appendices
  7. Contributions of authors
  8. Declarations of interest
  9. Sources of support

Description of the condition

Cancer cachexia is defined as "a multi-factorial syndrome characterized by an ongoing loss of skeletal muscle mass, with or without a loss of fat mass, that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment" (Fearon 2011). Prevalence varies with cancer type, but is highest in people with cancer arising from the upper gastro-intestinal tract or lung, where over half of all patients are affected at the point of diagnosis (Fearon 2011; Laviano 2005). The pathophysiology of cancer cachexia is complex and characterized by a negative energy balance and abnormal metabolism (Fearon 2012; Tisdale 2009). The combination of a persistent inflammatory response, tumour-derived catabolic factors and a stress response, leads to reduced food intake, increased resting energy expenditure, and an overall loss of skeletal muscle mass; the result of reduced protein synthesis, increased protein breakdown and reduced insulin sensitivity (Evans 2008; Fearon 2011; Tisdale 2009). The loss of lean body mass contributes to a progressive decline in muscle strength and endurance (Stephens 2012; Weber 2009), exercise capacity (England 2012; Jones 2012) and physical activity levels (Dodson 2011; Wilcock 2008), and is associated with increased risk of dose-limiting chemotherapy toxicities (Prado 2007; Prado 2008; Prado 2009) and poor survival (Antoun 2013; Martin 2013).


Description of the intervention

There are no standard interventions for cancer cachexia and some consider it refractory once established, for example, in patients with progressive disease and a limited prognosis (Fearon 2011). As such, it is recommended that greater emphasis be placed on applying a proactive approach, early in the course of the disease, with the aim to maintain or slow down the loss of physical function (Fearon 2011; Muscaritoli 2010). Due to the complex nature of the condition, multimodal intervention is also considered necessary as it is unlikely that a single intervention will increase food intake, attenuate the metabolic disturbances and address the imbalance between muscle protein synthesis and breakdown (Fearon 2008). Three main component interventions are being developed alone or in combination (Solheim 2012): nutritional therapies to increase energy and protein intake (Dewey 2007); drug therapies to stimulate appetite and reduce inflammation (Berenstein 2005; Lee 2011; Reid 2012); and exercise therapies.

Exercise is defined by the American College of Sports Medicine as a "planned, structured and repetitive bodily movement done to maintain or improve one or more components of physical fitness" (Thompson 2010). Different types of exercise may use everyday activities, such as walking, or specialist equipment, such as free-weights, for the purposes of training. Exercise programmes also vary widely according to the frequency, intensity and type of training used, as well as contextual factors such as the programme setting and level of supervision. For example, both a hospital-based programme of twice weekly, high-intensity, stationary cycling for six weeks, and a home-based programme of low-intensity, flexibility training throughout chemotherapy would be defined as exercise (Thompson 2010).


How the intervention might work

Exercise may attenuate the effects of cancer cachexia via several mechanisms, including the modulation of muscle metabolism, insulin sensitivity and levels of inflammation (Maddocks 2012). Resistance exercise is a potent stimulator of muscle protein synthesis, particularly when performed in conjunction with the provision of amino acids (Glover 2010; Marimuthu 2011). Improved insulin action in peripheral tissues following exercise may inhibit muscle protein breakdown (Wang 2006). Exercise also triggers the formation of a cohort of cytokines from muscle fibers, including Interleukin-6, which increases insulin sensitivity and reduces the production of pro-inflammatory cytokines (Starckie 2003). Repeated exercise has an overall anti-inflammatory effect, which has been observed in healthy populations (Gleeson 2011) and patients with early stage cancer (Betof 2013). This effect would be beneficial in cancer cachexia as levels of systemic inflammation are associated with reduced weight, exercise capacity and survival (Macmillan 2013; Moses 2009; Proctor 2011). Thus, by preventing or slowing down the loss of lean body mass, exercise may ultimately help patients with or at risk of cancer cachexia maintain their independence for longer.


Why it is important to do this review

Despite a growing evidence base for nutritional and drug interventions for cancer cachexia, including Cochrane reviews (Berenstein 2005; Dewey 2007; Payne 2012; Reid 2012), studies of exercise interventions in the field are few in number. Reviews examining the use of exercise in cancer cachexia are generally narrative (Gould 2013), opinion based (Argilés 2012; Maddocks 2011; Maddocks 2012) and/or based on animal models of the condition (Argilés 2012). Nonetheless, there are reports of small studies from conference proceedings as well as ongoing/planned studies (e.g. Kaasa 2013). Thus, there is a need to synthesise the evidence for the use of exercise for cancer cachexia and, if data permit, explore the optimal programme characteristics for this group of patients.



  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Appendices
  7. Contributions of authors
  8. Declarations of interest
  9. Sources of support

The primary objective is to determine the effectiveness of exercise, compared to usual care or no treatment, on biomarkers and outcomes of cachexia in adults with cancer. Secondary objectives, subject to the availability of data, are to examine the acceptability and safety of exercise in this setting and to compare effectiveness according to the characteristics of the exercise intervention or patient population.



  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Appendices
  7. Contributions of authors
  8. Declarations of interest
  9. Sources of support

Criteria for considering studies for this review


Types of studies

Randomised controlled trials (RCTs) with a parallel, single-stage or cross-over design, including studies with a quasi-randomised allocation in cases where allocation concealment is described.


Types of participants

Study participants will be adults (≥18 years of age) with a histological or clinical diagnosis of cancer, meeting international criteria for cancer cachexia of any stage (Fearon 2011). Stages of cachexia will include:

  • pre-cachexia, defined as weight loss ≤ 5% with anorexia and metabolic changes;
  • cachexia, defined as weight loss > 5% in the past 6 months or Body Mass Index (BMI) < 20 kg/m2 and ongoing weight loss > 2% or sarcopenia, anorexia or systemic inflammation; and
  • refractory cachexia, defined as active catabolism, ongoing weight loss, not responsive to treatment and life expectancy of < 3 months (Fearon 2011).

Where baseline demographic data are insufficient to assess participants against these criteria we will contact the study authors to seek additional data.

We will aim to include studies which are relevant to the review objectives, but which were not performed specifically to address cancer cachexia; e.g. studies in groups with advanced cancer. As such, studies will be included where at least half of the study population falls within the definitions outlined above. Participants may be studied in any hospital or community setting. Studies relating to participants during or following treatment with curative intent, or with no evidence of current disease, will not be included.


Types of interventions

We will include studies examining any programme of exercise offered as a sole intervention or in combination with another intervention. Programmes using aerobic/endurance training, resistance training or a combination of both will be considered. Programmes are expected to vary in terms of session length (minutes) and frequency (sessions/week), intensity of training (low, moderate, high) and overall duration (weeks). There will be no restriction on these or other programme characteristics including the setting in which the programme is offered (hospital/centre/home) and level of supervision (none, minimal, close). Interventions will be compared to either no treatment, usual care, or an active control group, e.g. a nutritional or drug intervention.


Types of outcome measures


Primary outcomes

The primary outcome will be lean body mass assessed immediately following a programme of exercise.


Secondary outcomes

Secondary outcomes include adherence to prescribed programmes, occurrence of adverse events and, subject to availability of data, muscle strength and endurance, maximal and submaximal exercise capacity, fatigue, and health-related quality of life.


Search methods for identification of studies


Electronic searches

An electronic search strategy using a combination of terms based on the target population, intervention, comparator and outcomes has been developed. The version that will be run on MEDLINE can be found in Appendix 1. It will be adapted where necessary for the other databases listed below. We will search the following electronic databases from their start date:

  • CENTRAL, DARE and HTA - Health Technology Assessments (onThe Cochrane Library);
  • ISI Web of Science;
  • LILACS (Latin American and Caribbean Health Sciences);
  • PEDro (the Physiotherapy Evidence Database);
  • SciVerse SCOPUS;
  • Biosis Previews PreMedline;
  • Open Grey (System for Information on Grey Literature).

We will identify ongoing studies using:


Searching other resources

We will handsearch the following sources: The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD); the American Cancer Society; the British Association for Cancer Research (BACR); and the European Clinical Guidelines. We will check reference lists of relevant studies and reports citing all retrieved studies.We will contact corresponding authors of retrieved studies, experts and organizations in the field to seek potentially relevant research material, including unpublished and ongoing studies.


Data collection and analysis


Selection of studies

Reference management software will be used to merge results from different electronic databases and remove duplicate studies. Two review authors (AJG, VS or SV) will independently assess titles and abstracts of articles for relevance (Higgins 2011a). We will obtain full-text reports of potentially relevant studies for assessment against the inclusion criteria. If missing information impairs the study selection, study authors will be contacted by email to clarify the necessary information. Any disagreements in the selection of studies will be discussed and resolved by consensus from both review authors. In cases of persistent disagreement, a third author (MSP or MM) will be consulted. No language restrictions will be applied in the selection of studies.

We will include a PRISMA study flow diagram in the full review (Liberati 2009) to document the screening process, as recommended in Part 2, Section 11.2.1 of the Cochrane Handbook (Higgins 2011a).


Data extraction and management

Two review authors (AJG and VS or SV) will independently extract data from the included studies. An online extraction form will be developed to store data relating to the study source and eligibility, methods and bias (study design, sequence generation, allocation sequence concealment, blinding), participants (number, age, sex, ethnicity, diagnosis, disease severity, setting) and intervention (exercise type and intensity, session length and frequency, and overall programme duration), adherence to the exercise programme (either self-reported or objective) and the occurrence of any adverse events. Disagreements will be discussed and resolved by consensus from all three review authors.

Outcome data collected at baseline, immediately following a programme of exercise and at first follow-up will include:

  • lean body mass, generally assessed by anthropometry, e.g. skin fold thickness, or imaging, e.g. dual x-ray absorptiometry, and expressed as a weight (e.g. kilograms, kg), cross-sectional area (square centimetres, cm2) or volume (cubic centimetres, cm3) normalised to height;
  • muscle strength, either isometric or isotonic, generally assessed using myometry and expressed as a measure of force (e.g. kilograms, kg, or Newton metres, Nm);
  • muscle endurance, generally assessed as time or number of repetitions to a specified decline in muscle performance;
  • maximal and submaximal exercise capacity, generally assessed by a walking or cycling test and expressed as a measure of oxygen uptake (VO2) or performance, e.g. distance walked in metres (m);
  • fatigue, generally assessed on a numerical or categorical scale with a higher score representing more severe fatigue;
  • health-related quality of life, generally assessed on a numerical or categorical scale with a higher score representing a better quality of life. We will examine the content items and known psychometric properties of instruments used.


Assessment of risk of bias in included studies

Two authors (AJG and VS or SV) will independently assess each study for risk of bias using the Cochrane Collaboration's tool, which addresses seven specific domains: sequence generation, allocation concealment, blinding of study participants and personnel, blinding of outcome assessment, completeness of outcome data, selective reporting and other potential sources of bias, for example carry-over or blocking, where bias may be introduced. For each domain, the tool first identifies what is reported to have happened in the study. Where it was unclear, information to aid this assessment will be sought from additional study reports, protocols, published comments and personal contact with study authors. Thereafter, a judgement will be made as to the level of risk of bias for that domain: low, high or unclear (Higgins 2011b).


Measures of treatment effect

Considering the review objectives and outcomes, counts, dichotomous, categorical and continuous data may be extracted.

Outcome data will be analysed as continuous when possible. In cases where there are missing data or insufficient data to perform meta-analysis, we will attempt to contact the study authors. The mean difference (MD) or standardised mean difference (SMD) in outcome between the intervention and control group will be calculated with 95% confidence intervals (CI) (Deeks 2011).


Unit of analysis issues

In parallel-group randomised controlled trials, the individual patient will be considered as the unit of analysis. If we include cross-over randomised controlled trials, both periods will be analysed, separated by periods, and altogether. If we include cluster-randomised trials, the unit of analysis will be the group.


Dealing with missing data

Authors will be contacted by email if the primary studies do not report the outcome measures of interest, or do not describe randomisation, or do not describe intention-to-treat analysis or have any other missing data, detected by AJG and VS or SV. If no answer is obtained from authors, the findings will be presented and discussed in the main text.


Assessment of heterogeneity

We will assess clinical heterogeneity using the I2 statistic (Higgins 2002; Higgins 2003) to quantify inconsistency across trial conditions and its impact on the meta-analysis. We will also assess the percentage of the variability in effect estimates which is due to the condition rather than sampling error, determined by the Chi2 test. Ideally an inverse variable fixed-effect model will be used to estimate the overall direction, size and consistency of an effect from exercise immediately post-programme. If considerable (I2 > 50%) or substantial clinical heterogeneity (I2 > 75%) is confirmed, we will apply a random-effects model or separate fixed-effect model calculation to estimate an effect from exercise for subgroup (see below) (Deeks 2011).


Assessment of reporting biases

If there are ≥10 included studies, a funnel plot test for asymmetry will be conducted to assess for any evidence of reporting bias.


Data synthesis

Where there are sufficient data and consistent or comparable outcomes, we will perform a meta-analysis using an inverse variable fixed-effect model to estimate the overall direction, size and consistency of an effect from exercise immediately post-programme. For other types of data, likely to arise from secondary outcomes, findings from individual studies will be described or presented in tabular form. We also plan to create a 'Summary of findings' table using the methods and recommendations described in Section 8.5 and Section 12 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011b) using the GRADEpro software.


Subgroup analysis and investigation of heterogeneity

Where sufficient data are available, we will use descriptive comparisons to consider differences in effect between subgroups according to the following participant characteristics: type of cancer (lung, pancreatic, etc.); stage of cachexia (pre-cachexia, cachexia, refractory cachexia Fearon 2011), and intervention characteristics; type of exercise (aerobic, resistance, combined), intensity of exercise (light, moderate, high).


Sensitivity analysis

Where sufficient data are available, we will perform a sensitivity analysis to consider the difference in pooled effect when studies at high or unclear risk of bias, or those with substantial (>20%) missing data, are omitted from analyses. We will present findings in tabular format.



  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Appendices
  7. Contributions of authors
  8. Declarations of interest
  9. Sources of support

The authors acknowledge Dr Fiona Cramp and Yvonne Roy for their comments on the protocol and Jane Hayes for developing the search strategy. We thank the Cochrane Handbook Study Group from the Brazilian Cochrane Centre for the opportunity to discuss Cochrane methodology.



  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Appendices
  7. Contributions of authors
  8. Declarations of interest
  9. Sources of support

Appendix 1. MEDLINE search strategy for Ovid

1        exp Neoplasms/

2        (cancer* or tumor* or tumour* or neoplas* or malignan* or carcinoma* or adenocarcinoma* or choricarcinoma* or leukemia* or leukaemia* or metastat* or sarcoma* or teratoma*).mp.

3        1 or 2

4        exp Weight Loss/

5        (cachexia or cachexic).mp.

6        exp Malnutrition/

7        (weight or underweight or malnutrition or wasting).mp.

8        4 or 5 or 6 or 7

9        exp Exercise/

10      exp Exercise Movement Techniques/

11      exp Exercise Therapy/

12      Physical Fitness/

13      (exercis* or aerobic* or resistance* or strength* or walk* or endurance*).mp.

14      (physical* adj5 (fit* or activ* or movement*)).mp.

15      9 or 10 or 11 or 12 or 13 or 14

16      3 and 8 and 15

17      randomized controlled

18      controlled clinical

19      randomized.ab.

20      placebo.ab.

21      clinical trials as

22      randomly.ab.

23      trial.ti.

24      17 or 18 or 19 or 20 or 21 or 22 or 23

25      16 and 24


mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier

pt=publication type


sh=subject heading



Contributions of authors

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Appendices
  7. Contributions of authors
  8. Declarations of interest
  9. Sources of support

AJG co-ordinated and is the guarantor of the protocol. All authors were involved in the planning and drafting of the protocol, and approve the final version of the protocol. AJG, VS, SP will search for, extract data from and assess risk of bias in studies, enter data into RevMan (RevMan 2012) and perform the analysis.


Declarations of interest

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Appendices
  7. Contributions of authors
  8. Declarations of interest
  9. Sources of support

The authors have no involvement in any organisation or entity with a vested interest in the outcomes of this review. MM is funded by an NIHR Post-Doctoral Fellowship award. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.


Sources of support

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Appendices
  7. Contributions of authors
  8. Declarations of interest
  9. Sources of support

Internal sources

  • None, Not specified.


External sources

  • None, Not specified.


Additional references

  1. Top of page
  2. Abstract
  3. Background
  4. Objectives
  5. Methods
  6. Acknowledgements
  7. Appendices
  8. Contributions of authors
  9. Declarations of interest
  10. Sources of support
  11. Additional references
Antoun 2013
  • Antoun S, Lanoy E, Iacovelli R, Albiges-Sauvin L, Loriot Y, Merad-Taoufik M, et al. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer 2013;25:2821-8.
Argilés 2012
  • Argilés JM, Busquets S, López-Soriano FJ, Costelli P, Penna F. Are there any benefits of exercise training in cancer cachexia?. Journal of Cachexia Sarcopenia and Muscle 2012;3:73-6.
Berenstein 2005
Betof 2013
  • Betof AS, Dewhirst MW, Jones LW. Effects and potential mechanisms of exercise training on cancer progression: a translational perspective. Brain, Behavior, and Immunity 2013;30:S75-S87.
Deeks 2011
  • Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Chichester: John Wiley & Sons, 2011.
Dewey 2007
Dodson 2011
  • Dodson S, Baracos VE, Jatoi A, Evans WJ, Cella D, Dalton JT, et al. Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annual Review of Medicine 2011;62:265-79.
England 2012
Evans 2008
Fearon 2008
Fearon 2011
  • Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. The Lancet Oncology 2011 May;12(5):489-95. [PUBMED: 21296615]
Fearon 2012
Gleeson 2011
  • Gleeson M, Bishop NC, Stensel DJ, Lindley MR, Mastana SS, Nimmo MA. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nature Reviews. Immunology 11;9:607-15.
Glover 2010
  • Glover EI, Phillips SM. Resistance exercise and appropriate nutrition to counteract muscle wasting and promote muscle hypertrophy. Current Opinion in Clinical Nutrition and Metabolic Care 2010;13:630-4.
Gould 2013
Higgins 2002
Higgins 2003
Higgins 2011a
  • Higgins JPT, Deeks JJ. Selecting studies and collecting data. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley & Sons, 2011.
Higgins 2011b
  • Higgins JPT, Altman DG. Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley & Sons, 2011.
Jones 2012
Kaasa 2013
  • Kaasa S, Fearon K. A feasibility study of multimodal exercise/nutrition/anti-inflammatory treatment for cachexia - the Pre-MENAC study. 2013. [:]
Laviano 2005
  • Laviano A, Meguid MM, Inui A, Muscaritoli M, Rossi-Fanelli F. Therapy insight: cancer anorexia-cachexia syndrome-when all you can eat is yourself. Nature Clinical Practice Oncology 2005;2:159-65.
Lee 2011
Liberati 2009
  • Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidiset JPA, al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Annals of Internal Medicine 2009;151(4):W-65-W-94.
Macmillan 2013
Maddocks 2011
  • Maddocks M, Murton AJ, Wilcock A. Improving muscle mass and function in cachexia: non-drug approaches. Current Opinion in Supportive and Palliative Care 2011;5(4):361-4. [DOI: 10.1097/SPC.0b013e32834bdde3]
Maddocks 2012
  • Maddocks M, Murton AJ, Wilcock A. Therapeutic exercise in cancer cachexia. Critical Reviews in Oncogenesis 2012;17:285-92.
Marimuthu 2011
Martin 2013
  • Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. Journal of Clinical Oncology 2013;31(12):1539-47.
Moses 2009
  • Moses AG, Maingay J, Sangster K, Fearon KC, Ross JA. Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: relationship to acute phase response and survival. Oncology Reports 2009;21:1091-5.
Muscaritoli 2010
  • Muscaritoli M, Anker SD, Argiles J, Aversa Z, Bauer JM, Biolo G, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by Specialist Interest Groups (SIG) ‘cachexia –anorexia in chronic wasting diseases’ and ‘nutrition in genetics’. Clinical Nutrition 2010;29:154-9.
Payne 2012
Prado 2007
  • Prado CM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clinical Cancer Research 2007;13:3264-8.
Prado 2008
  • Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncology 2008;9:629-35.
Prado 2009
  • Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clinical Cancer Research 2009;15:2920-6.
Proctor 2011
  • Proctor MJ, Morrison DS, Talwar D, Balmer SM, O'Reilly DS, Foulis AK, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. British Journal of Cancer 2011;104:726-34.
Reid 2012
RevMan 2012
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Solheim 2012
Starckie 2003
  • Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK. Exercise and IL-6 infusion inhibit endotoxin-induced TNFα production in humans. FASEB Journal 2003;17:884-6.
Stephens 2012
  • Stephens NA, Gray C, MacDonald AJ, Tan BH, Gallagher IJ, Skipworth RJ, et al. Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function. Clinical Nutrition 2012;31:499-505.
Thompson 2010
  • Thompson WR, Gordon NF, Pescatello LS. ACSM's Guidelines for Exercise Testing and Prescription. 8th Edition. Lippincott Williams & Wilkins, 2010.
Tisdale 2009
Wang 2006
  • Wang X, Hu Z, J Hu, Du J, Mitch WE. Insulin resistance accelerates muscle protein degradation: activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology 2006;147(9):4160-8.
Weber 2009
  • Weber MA, Krakowski-Roosen H, Schroder L, Kinscherf R, Krix M, Kopp-Schneider A, et al. Morphology, metabolism, microcirculation, and strength of skeletal muscles in cancer-related cachexia. Acta Oncologica 2009;48:116-24.
Wilcock 2008
  • Wilcock A, Maddocks M, Lewis M, England R, Manderson C, et al. Symptoms limiting activity in cancer patients with breathlessness on exertion: ask about muscle fatigue. Thorax 2008;63:91-2.